Investors purchased shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) on weakness during trading on Thursday. $49.17 million flowed into the stock on the tick-up and $35.90 million flowed out of the stock on the tick-down, for a money net flow of $13.27 million into the stock. Of all stocks tracked, Zimmer Biomet had the 28th highest net in-flow for the day. Zimmer Biomet traded down ($0.24) for the day and closed at $122.29
Several analysts recently weighed in on the stock. ValuEngine upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday. Canaccord Genuity reiterated a “hold” rating and issued a $132.00 target price on shares of Zimmer Biomet in a report on Friday, January 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zimmer Biomet in a report on Friday, January 5th. Goldman Sachs Group upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price target for the company in a research note on Tuesday, December 19th. Finally, Oppenheimer restated a “buy” rating on shares of Zimmer Biomet in a research note on Tuesday, December 19th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Zimmer Biomet currently has a consensus rating of “Buy” and a consensus target price of $137.42.
The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The stock has a market cap of $24,760.44, a P/E ratio of 15.15, a P/E/G ratio of 1.90 and a beta of 1.15.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.79 EPS. analysts anticipate that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet’s payout ratio is currently 30.19%.
Hedge funds have recently modified their holdings of the stock. Bank of Nova Scotia Trust Co. acquired a new position in shares of Zimmer Biomet during the third quarter worth $112,000. FNY Managed Accounts LLC acquired a new position in shares of Zimmer Biomet during the third quarter worth $117,000. BB&T Investment Services Inc. acquired a new position in shares of Zimmer Biomet during the second quarter worth $144,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Zimmer Biomet during the third quarter worth $140,000. Finally, Sandy Spring Bank grew its stake in shares of Zimmer Biomet by 5.4% during the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 85.92% of the company’s stock.
WARNING: “Investors Buy Zimmer Biomet (ZBH) on Weakness” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/investors-buy-zimmer-biomet-zbh-on-weakness.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.